M&A Deal Summary

Molecular Designs Acquires Lamda Biotech

On September 25, 2024, Molecular Designs acquired life science company Lamda Biotech

Acquisition Highlights
  • This is Molecular Designs’ 1st transaction in the Life Science sector.
  • This is Molecular Designs’ 1st transaction in the United States.
  • This is Molecular Designs’ 1st transaction in Missouri.

M&A Deal Summary
Date 2024-09-25
Target Lamda Biotech
Sector Life Science
Buyer(s) Molecular Designs
Deal Type Add-on Acquisition

Target

Lamda Biotech

St. Louis, Missouri, United States
Lamda Biotech is a provider of research products for application in molecular biology, functional genomics, proteomics, and gene therapy. The Company offers PCR products, RT-PCR reagents, RT-qPCR kits, Direct-PCR genotyping kits, DNA ladders, SafeStain, and other protein and cell biology products. Lamda Biotech is headquartered in St. Louis, Missouri.

Search 200,577 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Molecular Designs

Birmingham, Alabama, United States
Category Company
Founded 2019
Sector Life Science
DESCRIPTION

Molecular Designs is a developer, manufacturer, and supplier of multiplex assays for molecular testing and research. Utilizing time-tested PCR to identify pathogens rapidly not only improves patient care but also advances antibiotic stewardship. Molecular Designs was founded in 2019 and is based in Birmingham, Alabama.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Missouri) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal